Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.

S&P 500, Banco Santander, Gilead Sciences Inc. Read 's Market Analysis on Investing.com ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

From parades to parties and everything in between, this guide has all the details you need to show your pride this June. 👇 #bham #pride #June #fun #events #downtownbham GH ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

Pride month is here, Bham! We’ve put together a guide of ways to directly join the fight against HIV + support all members of ...